<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">Finally, since the SARS-COV-2 uses angiotensin-converting enzyme 2 (ACE2) as the receptor binding domain for its spike protein, some authors hypothesize that angiotensin receptor 1 (AT1R) blockers such as losartan or telmisartan, could have some beneficial in patients infected by COVID-19 who experienced pneumonia [
 <xref ref-type="bibr" rid="CR33">33</xref>â€“
 <xref ref-type="bibr" rid="CR35">35</xref>].
</p>
